Mind Medicine Pays JR Rahn $6.7 Million In Shares To Leave Leadership Roles

It seems that after selling $24.7 million in company stock, JR Rahn is looking to step down from Mind Medicine (NEO: MMED) (NASDAQ: MNMD). The firm this morning announced that Rahn will be stepping down from his role as both CEO and director of the company in which in co-founded. The best part, is he will be paid to do so.

As part of the agreement for Rahn to step down from his role, the company has notably agreed to issue him 1.5 million subordinate voting shares. Effectively, Rahn will see a pay day equivalent to $6.68 million just for leaving his role as an executive of the company.

Taking Rahn’s place as CEO of the company will be that of Robert Barrow, the firms chief development officer, effective immediately. The company has also commence a “comprehensive search for a chief executive officer,” for which Barrow is to be a candidate, with Rahn advising the firm on its transition.

The transition reportedly will “enable the company to pursue aggressively its clinical development programs and development of its companion innovative digital technologies.” Commenting on his transition, Rahn stated, “Our work to date and ability to raise capital has taken us leaps and bounds closer to that vision. This chief executive officer transition is a natural progression for MindMed as the Company heads into later stage clinical trials.”

Mind Medicine last traded at $4.45 on the Neo.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Copper Juniors Could Explode After This Trade War Move | Christian Easterday – Hot Chili

Silver Is Rarer Than Gold, And the Market’s Waking Up | Shawn Khunkhun – Dolly Varden Silver

Gold Will Hit North of $4,000: Who’s Actually Producing? | Shane Williams – West Red Lake

Recommended

ESGold Sees ANT Survey Reveal Vertically Continuous System To 1,200 Metres Depth

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Related News

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are...

Monday, June 14, 2021, 03:38:00 PM

Mind Medicine To Conduct $25.0 Million Bought Deal Financing

Mind Medicine (CEO: MMED) announced that it will be conducting a bought deal financing this...

Friday, October 9, 2020, 09:01:05 AM

MindMed To Begin Trading On The Nasdaq April 27

MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning...

Friday, April 23, 2021, 09:11:58 AM

Activist Investor Calls For MindMed CEO’s Termination Due To Alleged Fraudulent Acts

FCM MM Holdings, one of Mind Medicine’s (NEO: MMED) shareholders with a 6.1% stake, has...

Thursday, November 3, 2022, 03:10:00 PM

MindMed Starts Clinical Trial For Intravenous DMT

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the start of...

Wednesday, July 28, 2021, 10:22:00 AM